Medical Doctor Program year 2021 Reported 2019–2021 Source: CMS Open Payments, 2026 publication

Gerald Ravitz

Urology Pottsville, PA Medical Doctor

NPI 1174591515 CMS profile 144260

100 E Union St, Pottsville, PA 17901

Open in the dashboard

General payments

$1,120

62 records reported · program years 2019–2021

Research payments

$0

Paid to them · None reported · program years 2019–2021

Ownership & investment interest

$0

3 holdings reported · through program year 2021

Through program year 2021, Gerald Ravitz of Pottsville, PA is reported in the CMS Open Payments database as having received $1,120 across 62 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 34th percentile of Urology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2021 General $375 22
2020 General $537 25
2019 General $208 15
2021 Ownership $0 1
2020 Ownership $0 1
2019 Ownership $0 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Gerald Ravitz
  • Urology median
  • Middle half of Urology
  • National median

In program year 2025, general payments to Gerald Ravitz were reported at $0. Among 9,461 Urology profiles paid that year, the median was $629 and the middle half received between $190 and $1,620.

Show as a table
Year Gerald Ravitz Urology median Middle half National median
2019 $208 $480 $147–$1,201 $163
2020 $537 $246 $87–$645 $114
2021 $375 $358 $111–$1,000 $132
2022 $0 $476 $143–$1,263 $149
2023 $0 $560 $168–$1,461 $160
2024 $0 $563 $170–$1,464 $164
2025 $0 $629 $190–$1,620 $169

Breakdown

Who paid General payments · program years 2019–2021
  1. Janssen Biotech, Inc. $396 25 payments
  2. Astellas Pharma US Inc $371 18 payments
  3. AbbVie, Inc. $130 7 payments
  4. Pfizer Inc. $105 5 payments
  5. TOLMAR Pharmaceuticals, Inc. $50 2 payments
  6. Bayer HealthCare Pharmaceuticals Inc. $18 1 payment
  7. Foundation Medicine, Inc. $13 1 payment
  8. Merck Sharp & Dohme Corporation $13 1 payment
  9. Urovant Sciences Inc $12 1 payment
  10. Retrophin, Inc. $11 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2021
  1. Food and Beverage $829 58 payments
  2. Education $291 4 payments
Products named General payments · program years 2019–2021
  1. ERLEADA $396 25 payments
  2. XTANDI $219 14 payments
  3. MYRBETRIQ $113 7 payments
  4. LUPRON DEPOT Endocrinology $76 4 payments
  5. LUPRON DEPOT Endocrinology $54 3 payments
  6. ELIGARD Prostate Cancer $27 1 payment
  7. ELIGARD Prostate Cancer $23 1 payment
  8. Nubeqa $18 1 payment
  9. FOUNDATIONONE CDX $13 1 payment
  10. FOUNDATIONONE $13 1 payment
  11. Other $88 7 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

62 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Urology in Pennsylvania

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2021

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record